Literature DB >> 22890768

Utilization of omeprazole to augment subtherapeutic voriconazole concentrations for treatment of Aspergillus infections.

Natalie K Boyd1, Cindy L Zoellner, Mark A Swancutt, Kavita P Bhavan.   

Abstract

Voriconazole is the preferred antifungal agent for Aspergillus infections. Therapeutic drug monitoring is recommended to achieve target concentrations and prevent toxicity. However, variable pharmacokinetics, cytochrome P450 polymorphisms, and extensive drug-drug interactions can contribute to subtherapeutic concentrations. We report a voriconazole "boosting" effect of omeprazole to achieve target concentrations for the treatment of Aspergillus in a patient who had persistently subtherapeutic trough concentrations.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22890768      PMCID： PMC3486541          DOI： 10.1128/AAC.00700-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms.

Authors:  J W Ko; N Sukhova; D Thacker; P Chen; D A Flockhart
Journal:  Drug Metab Dispos       Date:  1997-07       Impact factor: 3.922

2.  Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients.

Authors:  Peter F Troke; Hans P Hockey; William W Hope
Journal:  Antimicrob Agents Chemother       Date:  2011-07-18       Impact factor: 5.191

3.  Voriconazole therapeutic drug monitoring.

Authors:  J Smith; N Safdar; V Knasinski; W Simmons; S M Bhavnani; P G Ambrose; D Andes
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

Review 4.  Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.

Authors:  S A Scott; K Sangkuhl; E E Gardner; C M Stein; J-S Hulot; J A Johnson; D M Roden; T E Klein; A R Shuldiner
Journal:  Clin Pharmacol Ther       Date:  2011-06-29       Impact factor: 6.875

5.  Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis.

Authors:  Yukihiro Hamada; Yoshinori Seto; Kazuo Yago; Masakazu Kuroyama
Journal:  J Infect Chemother       Date:  2012-01-11       Impact factor: 2.211

6.  Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients.

Authors:  Steve Trifilio; Gennethel Pennick; Judy Pi; Jennifer Zook; Mary Golf; Kimberley Kaniecki; Seema Singhal; Stephanie Williams; Jane Winter; Martin Tallman; Leo Gordon; Olga Frankfurt; Andrew Evens; Jayesh Mehta
Journal:  Cancer       Date:  2007-04-15       Impact factor: 6.860

7.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.

Authors:  Raoul Herbrecht; David W Denning; Thomas F Patterson; John E Bennett; Reginald E Greene; Jörg-W Oestmann; Winfried V Kern; Kieren A Marr; Patricia Ribaud; Olivier Lortholary; Richard Sylvester; Robert H Rubin; John R Wingard; Paul Stark; Christine Durand; Denis Caillot; Eckhard Thiel; Pranatharthi H Chandrasekar; Michael R Hodges; Haran T Schlamm; Peter F Troke; Ben de Pauw
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

8.  Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens.

Authors:  L Purkins; N Wood; P Ghahramani; K Greenhalgh; M J Allen; D Kleinermans
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

9.  Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.

Authors:  Andres Pascual; Thierry Calandra; Saskia Bolay; Thierry Buclin; Jacques Bille; Oscar Marchetti
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079

10.  Effect of omeprazole on the steady-state pharmacokinetics of voriconazole.

Authors:  Nolan Wood; Keith Tan; Lynn Purkins; Gary Layton; Julia Hamlin; Diane Kleinermans; Don Nichols
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335
  10 in total
  8 in total

1.  CNS Mold Infections.

Authors:  Jennifer L Lyons
Journal:  Curr Infect Dis Rep       Date:  2013-10-13       Impact factor: 3.725

Review 2.  Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.

Authors:  Leon Fisher; Alexander Fisher
Journal:  Clin Drug Investig       Date:  2017-07       Impact factor: 2.859

3.  Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies.

Authors:  Martin Hoenigl; Wiebke Duettmann; Reinhard B Raggam; Katharina Seeber; Katharina Troppan; Sonja Fruhwald; Florian Prueller; Jasmin Wagner; Thomas Valentin; Ines Zollner-Schwetz; Albert Wölfler; Robert Krause
Journal:  Antimicrob Agents Chemother       Date:  2013-04-29       Impact factor: 5.191

4.  In vitro study of the variable effects of proton pump inhibitors on voriconazole.

Authors:  Krista L Niece; Natalie K Boyd; Kevin S Akers
Journal:  Antimicrob Agents Chemother       Date:  2015-06-29       Impact factor: 5.191

5.  Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Thomas F Patterson; George R Thompson; David W Denning; Jay A Fishman; Susan Hadley; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; M Hong Nguyen; Brahm H Segal; William J Steinbach; David A Stevens; Thomas J Walsh; John R Wingard; Jo-Anne H Young; John E Bennett
Journal:  Clin Infect Dis       Date:  2016-06-29       Impact factor: 9.079

6.  Is It Time for Systematic Voriconazole Pharmacogenomic Investigation for Central Nervous System Aspergillosis?

Authors:  Fanny Lanternier; Olivier Lortholary; François Danion; Vincent Jullien; Claire Rouzaud; Manal Abdel Fattah; Simona Lapusan; Romain Guéry; Naïke Bigé; Marjolaine Morgand; Nicolas Pallet
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

7.  Therapeutic drug monitoring of voriconazole: a case report of multiple drug interactions in a patient with an increased CYP2C19 activity.

Authors:  Yassine Bouatou; Caroline Flora Samer; Kuntheavy Roseline Ing Lorenzini; Youssef Daali; Samira Daou; Marc Fathi; Michela Rebsamen; Jules Desmeules; Alexandra Calmy; Monica Escher
Journal:  AIDS Res Ther       Date:  2014-08-04       Impact factor: 2.250

8.  Influence of CYP2C19*2/*17 genotype on adverse drug reactions of voriconazole in patients after allo-HSCT: a four-case report.

Authors:  Sienkiewicz Beata; Urbaniak-Kujda Donata; Dybko Jarosław; Wróbel Tomasz; Wiela-Hojeńska Anna
Journal:  J Cancer Res Clin Oncol       Date:  2017-02-28       Impact factor: 4.553
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.